
How to use WHO's family planning guidelines and tools

Mary Eluned Gaffield Promoting Family Planning Team Department of Reproductive Health and Research

Training Course in Sexual and Reproductive Health Research Geneva 2013






Learning objectives

- To understand the purpose of WHO's family guidelines and tools.
- To be able to identify and apply medical eligibility criteria and practice recommendations for family planning service delivery.
- To know how to use family planning tools for service provision.






The need for evidence-based guidance

- To base family planning practices on the best available published evidence
- To address misconceptions regarding who can safely use contraception
- To reduce medical barriers
- To improve access and quality of care in family planning






WHO guidelines and tools



(d) World Healt) Organization




hrp

Guidance developed through consensus

Expert Working Group meetings:


- Country experts
- Representatives of:
 - UNFPA
 - World Bank
 - IPPF
 - USAID
 - CDC
 - NICHD
 - Engender Health

- FHI
- JHU/CCP
- JHPIEGO
- Intra-Health
- Georgetown University Medical Center
- Management Sciences for Health





Medical eligibility criteria for contraceptive use (MEC)




Fourth edition, 2009

COC Barrier methods IUDs Farthly meanment water and the Coc Factorian meanment of the Coc Factorian electronic interaction desause Cicc cellular interaction coc factorian and the coc Factorian and the late metaolic interaction for the Coc Factorian methods IUDs hereity, waterment barrier factorian coc factorian termination interaction coc factorian termination interaction coc factorian termination interaction coc factorian termination control coc factorian termination coc factorian ter



Purpose: Who can safely use contraceptive methods?

- First published in 1996, revised through expert meetings held in 2000, 2003, and 2008
- Fourth edition offers ≈ 1800 recommendations for 19 methods
- Available in English, French, Spanish, Arabic, Chinese, Turkish, Romanian, Portuguese, Laotian, Vietnamese, Mongolian








Classification of recommendations

- **Divided** into four categories:
 - 1 = a condition for which there is no restriction for the use of the contraceptive method,
 - 2 = a condition where the advantages of using the method generally outweigh the theoretical or proven risks,
 - 3 = a condition where the theoretical or proven risks usually outweigh the advantages of using the method,
 - 4 = a condition which represents an unacceptable health risk if the contraceptive method is used.






Classification of recommendations - continued

- Four categories can be simplified where resources for clinical judgement are limited:
 - Woman is medically eligible to use the method (categories 1 & 2)
 - Woman is not medically eligible to use the method (categories 3 & 4)
- Initiation and continuation
 - Where warranted, recommendations will differ if a woman is starting a method (I = initiation) or continuing a method (C = continuation)
 - Example: women with current PID are a category '4' for initiating a copper IUD, but a category '2' for if they are continuing to use an IUD.
 - Unless noted, recommendations are the same for initiation and continuation of a method








Classification of recommendations - female and male surgical sterilization

- **Divided** into four categories:
 - Accept 'A' = There is no medical reason to deny sterilization to a person with this condition,
 - Caution 'C' = The procedure is normally conduced in a routine setting, but with extra preparation and precautions,
 - Delay 'D' = The procedure is delayed until the condition is evaluated and or corrected. Alternative temporary methods of contraception should be provided,
 - Special 'S' = The procedure should be undertaken in a setting with an experienced surgeon and staff, equipment needed to provide general anaesthesia, and other back-up medical support. The capacity to decide the most appropriate procedure and anaesthesia regimen is needed. Alternative temporary methods of contraception should be provided, if referral is required or there is otherwise any delay.






CONDITION	COC	CIC	P/R	POP	dmpa Net-en	LNG/ ETG Implants	Cu-IUD	LNG-IUD
l = Ini	tiation, C =	- Continuatio	on, BF = Br	eastfeeding	, NA = not	applicable		
BREAST DISEASE								
a) Undiagnosed mass	2*	2*	2*	2*	2*	2*	1	2
b) Benign breast disease	1	1	1	1	1	1	1	1
c) Family history of cancer	1	1	1	1	1	1	1	1
d) Breast cancer								
(i) current	4	4	4	4	4	4	1	4
 (ii) past and no evidence of current disease for 5 years 	3	3	3	3	3	3	1	3
ENDOMETRIAL CANCER							1 C	I C
	1	1	1	1	1	1	4 2	4 2
OVARIAN CANCER							I C	I C
	1	1	1	1	1	1	3 2	3 2
UTERINE FIBROIDS		-	-		-			a <u>k</u> i
a) Without distortion of the uterine cavity	1	1	1	1	1	1	1	1
b) With distortion of the uterine cavity	1	1	1	1	1	1	4	4

Source: Medical Eligibility Criteria for Contraceptive Use. WHO: Geneva, 2009.







SUMMARY TABLES

CONDITION	COC	CIC	P/R	POP	DMPA Net-en	LNG/ ETG Implants	Cu-IUD	LNG-IUD
[]]	nitiation, C =	Continuatio	on, BF = Bre	eastfeeding	g, NA = not	applicable		
PERSONAL CHARACTERIST	ICS AND REP	RODUCTIVE	HISTORY					
SMOKING								S
a) Age < 35	2	2	2	1	1	1	1	1
b) Age ≥ 35								
(i) <15 cigarettes/day	3	2	3	1	1	1	1	1
(ii) >15 cigarettes/day	4	3	4	1	1	1	1	1

(Source: Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva, 2009)






Case study: which methods are safe ?

- A 24 year old woman with a family history of breast cancer ?
 - COC ?
 - IUD ?
 - Injectable ?
 - Implants ?

- A 38 year old woman who smokes less than 1/2 pack of cigarettes per day ?
 - COC ?
 - IUD ?
 - Implants ?
 - Injectable ?





MEC Wheel



- Offers accessible MEC guidance for most commonly encountered medical conditions.
- Conditions that are either '1' or '2' on back of wheel.
- Locate condition of interest, then turn wheel to identify eligibility category.
- Available in many languages: English, French, Spanish, Chinese, Arabic, Mongolian, Azeri, Latvian, Lithuanian, Russian, Sri Lankan, Myanmar, Armenian, Nepali, Indonesian, Turkish, Burmese, Ukrainian, Khmer




Electronic wheel demonstration

 Electronic wheel allows you to consult common conditions easily

Now, please click this link to open the electronic wheel: http://www.who.int/reproductivehealth/publications/f amily_planning/wheel_v4_2010_EN.swf

Note: The electronic wheel was attached in this presentation with audio.






Selected practice recommendations for contraceptive use



Purpose: How to safely deliver contraceptive methods?

- First published in 2000, revised through expert meetings held in 2004 and 2008
 - Second edition offers 33 practice recommendations

Available in English, French, Spanish, Arabic, Chinese, Romanian, Portuguese, Russian, Vietnamese, Sri Lankan








Practice questions

Examples:

- when to start
- when to re-administer
- how to manage problems
 - missed pills
 - bleeding (progestogen-only methods and IUDs)
 - prophylactic antibiotics and IUD insertion
- what examinations and tests are required before starting a method







1. When can a woman start combined oral contraceptives (COCs)?

Note: The woman may be provided with COCs in advance with appropriate instructions on pill initiation, provided she is medically eligible.

Having menstrual cycles

- She can start COCs within 5 days after the start of her menstrual bleeding. No additional contraceptive protection is needed.
- She also can start COCs at any other time, if it is reasonably certain that she is not pregnant. If it has been more than 5 days since menstrual bleeding started, she will need to abstain from sex or use additional contraceptive protection for the next 7 days.

Amenorrhoeic


 She can start COCs at any time, if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days.

Postpartum (breastfeeding)*

- If she is more than 6 months postpartum and amenorrhoeic, she can start COCs as advised for other amenorrhoeic women.
- If she is more than 6 months postpartum and her menstrual cycles have returned, she can start COCs as advised for other women having menstrual cycles.
- * Additional guidance from the Medical eligibility criteria for contraceptive use. Third edition, 2004. Women less than 6 weeks postpartum who are primarily breastfeeding should not use COCs. For women who are more than 6 weeks but less than 6 months postpartum and are primarily breastfeeding, use of COCs is not usually recommended unless other more appropriate methods are not available or not acceptable.

Postpartum (non-breastfeeding)*

 If her menstrual cycles have not returned and she is 21 or more days postpartum, she can start COCs immediately, if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days.








Routine exams or tests

Exam or screening	Hormonal methods	IUD	Condoms / Spermicide s	
Breast exam	С	С	С	С
Pelvic exam	С	А	С	А
Cervical cancer	С	С	С	С
Routine lab tests	С	С	С	С
Hemoglobin	С	В	С	В
STI risk assessment	С	А	С	С
STI screening	С	В	С	С
Blood pressure	**	С	С	Α

Class A: essential and mandatory in all circumstances Class B: contributes substantially to safe and effective use Class C: does not contribute substantially to safe and effective use






Decision-making tool for family planning clients and providers




- A tool for providers and their clients. Contains evidence-based technical information
- Contains evidence-based technical information and a counseling process
- To be used with clients in the clinic
- Uses simple language
- Illustrations for clients










Improved counseling has the potential to :

Increase:

- Client satisfaction
- Provider satisfaction
- Correct use of methods
- Continuation of use


Reduce:

- Dropout from services
- Unnecessary health risks
- Method failure
- Unwanted pregnancy

















A structured counselling process




Main points on a CLIENT PAGE




Decision-making question: client needs to respond and participate before going to next page







Main points on a PROVIDER PAGE



Department of

Reproductive Health and Research



Counseling Icons








Ask if client has questions

Offer support

Check understanding

Listen carefully






hrp


-

Choosing a method



Choosing a method:

Do you have a method in mind?




If you do, let's talk about how well it suits your needs

- · What have you heard about it?
- What do you like about it?

If not, we can find a method right for you

Important for choosing a method: Do you need protection from pregnancy AND sexually transmitted infections?

- Focus on what she knows about the method
- 2. Check understanding of the method
- 3. Can also discuss other options





Best practices in FP counseling:

You can find a method right for you



No method in mind? We can discuss:

- Your experiences with family planning
- What you have heard about family planning methods
- Your plans for having children
- Protection from sexually transmitted infections (STIs) or HIV/AIDS
- Your partner's or family's attitudes
- Other needs and concerns



Focus on needs and situation


Comparing methods



2. Compare methods in light of needs and situation




Dual Protection



Dual Protection = Protection from pregnancy and STIs/HIV








Dual Protection

Do you have a method in mind?




Part of the decision-making process

Copper IUD

- Small device that fits inside the wornb
- Very effective
- Keeps working up to 10 years, depending on type
- We can remove it for you whenever you want
- Very safe
- Might increase menstrual bleeding or cramps
- No protection against STIs or HIV/AIDS

Do you want to know more about the IUD, or talk about a different method?


Special Needs




Reproductive Health and Research




Returning Clients








Returning Clients











Managing problems











Method Sections










go to next page.


another method, but not monthly injectable.


P2

Appendices: extra counseling tools



(d) World Heal Organizatio






8: Facts about STIs and HIV/AIDS


effective	Bpermibides	Minatia a secually transmitted infection (STI)?	Whatare HM and AIDS?	Teating, counselling, and treatment for HM/AIDS	
		 An STIIs an Imbolion hal can be spread from person to person by sexual combol. Some STIs can be transmitted by any sexual act that involves combolise ween the perist, usgina, anus and/or mouth. For best protection, a sougher chould use condomic, or a volid any contact in the genith area (notiviting that and analise). BTIs smay or may no toau ce symptoms. Some cause pain. Often, however, people (particularly women) may not know that they have an STI unit a mater problem de uslops. Bome common BTI coan be treated and oursed with antibiolics. These STE include genomose, chamydial intection, chamooid and sphills. Thichmonicalls, while usually not sexually tensmitted, also can be treated. Bome can not be oursed, including hepatits B, genital tenps, human papilloma unis (HPV) and HIV (see right). If a woman has an STI, she is all greater risk for some reproducture cancers, public instantacity in threate a sh, particularly in the base a center, public instantacity in the size and the sh papilloma units (HPV) and HIV (see right). If a woman has an STI, she is all greater risk for some reproducture cancers, public instantacity its access exclosing registrory, miscantage and HIV intection. Bome BTI coan out us instrikt for STIs, see Dual Protection eab, page DP2. 	 Clinis and young women are superiorized sixual intercourse due to social and biological uninerability. AIDB (Acquired Immune Deticiency Syndrome) is chemacterized by cartain dise are a that develop during the that cares of the HV inter ten gr dering the that cares of the HV inter ten gr ieri uniteated). Illnesses deuelop because HV progressiually wakters the Immune system and reduces the body's ability to tight disease (for example, pneumonia, table routosis, mataria, shingles or diarthoea). After a person contracts HV, digins and symptomic of dokine can armally take many years to develop. 	 A percentilloing title HIV usually looks and theirs healthy. Most people with HIV do not know that hey are carrying the utrus. To preuent intections and to promote access to care and treatment, it is important for a percente here with other HIV of the utrus. The only way to kill it a person has HIV is a blood lest. Blood lests can usually de let HIV 6 weeks after he percentes been exposed to her utrus. Positive lest insults need continuation before diagnosing or courseiling the patient. Recommend HIV lesting for all clients who way be attrike of acquiring HIV. The sing should always be uotuntary, based on informed consent, and be combined with courseiling. Assure client heat all he to are one to entitle. How a positive HIV lesting utiling. The sing and support, including couple courseiling. Broomage sexual partners to bill each other heir lest results (if his is notifiely. All the as appropriate. Are is vapolite HIV Retires appropriate. Are of 2005, ALDB has no definite sure and there is no vapilite. HIV estime is can be unal significantly enhance quality of the mate axistible for women here to right or the significantly enhance quality of the mate axistible to women here row on the HIV estime of an isoport. To preuentmone roo-child terremission of HIV, a wide ang of services should be made axistible for women hiung with HIV, including temily planning sendices, drugs to avoid transmission of HIV, and proper breas theding adultic and support. 	
		Anyone at n	Anyone at risk for STIs, including HIV, should use CONDOMS!		



Reproductive Choices and Family Planning for People with HIV




- Two-day training and job aid an adaptation of the Decision-Making Tool for Family Planning Clients and Providers
 - Developed as part of Integrated Management of Adolescent and Adult Illness (IMAI) series
- Field tested in Uganda and Lesotho
- Developed in collaboration with the INFO Project at Johns Hopkins Bloomberg School of Public Health
- First edition published in 2006 and available on WHO website






Road map of this counseling tool




Safer sex and living with HIV

- Can still enjoy sexual intimacy
- There are ways to lower risk
- Some sexual activities are safer than others







Do you know your partner's HIV status?

Questions about sexual relationships:

- Does client know the HIV status of sex partner(s)?
- Does partner(s) know client's HIV status?

If a partner's status is unknown:

- Discuss reasons that client's partner(s) should be tested for HIV.
 - Even if you are HIV positive, your partner may not be infected.
 - When both partners know their status, they can then know how best to protect themselves.
- When status is unknown, assume your partner is negative and needs protection from infection. Important to use condoms.

If a partner is HIV negative:

- Explain that it is common for a person who is HIV positive to have a partner who is HIV negative.
- HIV is not transmitted at every exposure, but HIV-negative partners are at a high risk of infection.
- Important to always use condoms or avoid penetrative sex.

If both you and your partner are HIV positive:

- If mutually faithful, the couple may choose not to use condoms and may choose another method for pregnancy protection.
- If not mutually faithful or faithfulness is uncertain, condoms should be used or penetrative sex avoided to prevent STIs.

How to use this page:

• Discuss HIV status of client and partner(s) so they can know how to best protect themselves.

For all

clients


- If client has not disclosed HIV status to partner, discuss benefits and risks of disclosure.
- Help client develop strategy for disclosure, if client is ready.
- Strongly encourage and help with partner testing and counselling.

Next step: Discuss safer sex and living with HIV (go to next page).


Preparing to disclose HIV status

- Who to tell?
- When to tell?
- How to tell? Make a plan.
- What you will say? Practice with client.
- What will you say or do if ...?
- If there is a risk of violence, discuss whether or not to disclose, or how to disclose with counsellor or friend present.

Family Planning: A Global Handbook for Providers



- Reference guide for family planning providers & summarizes WHO family planning guidance
- Launched in October 2007, updated in 2011
- Over 100,000 copies distributed
- Published by the INFO Project at the Johns Hopkins Bloomberg School of Public Health. Endorsed by nearly 50 organizations






Contents: Method chapters

- Combined oral contraceptives (COCs)
 - Patch
 - Vaginal Ring
- Combined injectable contraceptives (CICs)
- Emergency contraceptive pills
- Progestogen-only pills
- Progestogen-only injectables
- Implants
- Copper-bearing IUD
 - LNG-IUD

- Vasectomy
- Female sterilization
- Lactational amenorrhea method
- Fertility awareness-based methods
 - Withdrawal
- Condom
- Female condom
- Spermicides/diaphragm






Chapter Headings

- Key points
- Helping the Client Decide about Combined Oral Contraceptives (COCs)
- Side effects, health benefits, and risks
 - COCs and cancer
- Who can and cannot use combined oral contraceptives
 - Medical eligibility criteria
- Providing combined oral contraceptives
- Following up users of combined oral contraceptives
- Questions and Answers







CHAPTER 4

Progestin-Only Injectables


Key Points for Providers and Clients

- Bleeding changes are common but not harmful. Typically, irregular bleeding for the first several months and then no monthly bleeding.
- Return for injections regularly. Coming back every 3 months (13 weeks) for DMPA or every 2 months for NET-EN is important for greatest effectiveness.
- Injection can be as much as 2 weeks early or late. Client should come back even if later.
- Gradual weight gain is common.
- Return of fertility is often delayed. It takes several months longer on average to become pregnant after stopping progestinonly injectables than after other methods.

What Are Progestin-Only Injectables?

- The injectable contraceptives depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) each contain a progestin like the natural hormone progesterone in a woman's body. (In contrast, monthly injectables contain both estrogen and progestin. See Monthly Injectables, p. 81.)
- Do not contain estrogen, and so can be used throughout breastfeeding and by women who cannot use methods with estrogen.
- DMPA, the most widely used progestin-only injectable, is also known as "the shot," "the jab," the injection, Depo, Depo-Provera, Megestron, and Petogen.
- NET-EN is also known as norethindrone enanthate, Noristerat, and Syngestal. (See Comparing Injectables, p. 359, for differences between DMPA and NET-EN.)

Progestin-Only Injectables 59









- Given by injection into the muscle (intramuscular injection). The hormone is then released slowly into the bloodstream. A different formulation of DMPA can be injected just under the skin (subcutaneous injection). See New Formulation of DMPA, p. 63.
- Work primarily by preventing the release of eggs from the ovaries (ovulation).

How Effective?

More effective

Effectiveness depends on getting injections regularly: Risk of pregnancy is greatest when a woman misses an injection.

- As commonly used, about 3 pregnancies per 100 women using progestin-only injectables over the first year. This means that 97 of every 100 women using injectables will not become pregnant.
- When women have injections on time, less than 1 pregnancy per 100 women using progestin-only injectables over the first year (3 per 1,000 women).

Return of fertility after injections are stopped: An average of about 4 months longer for DMPA and 1 month longer for NET-EN than with most other methods (see Question 7, p. 79).

Protection against sexually transmitted infections (STIs): None

naios par 100 vuentes uting

Less

effective

Other possible physical changes:

Loss of bone density (see Question 10, p. 80)

Why Some Women Say They Like Progestin-Only Injectables

- · Do not require daily action
- Do not interfere with sex
- Are private: No one else can tell that a woman is using contraception

Side Effects, Health Benefits, and Health Risks

NET-EN affects bleeding patterns less than DMPA. NET-EN users have

fewer days of bleeding in the first 6 months and are less likely to have no

Side Effects (see Managing Any Problems, p. 75)

Changes in bleeding patterns including, with DMPA:

monthly bleeding after one year than DMPA users.

Some users report the following:

First 3 months:

Irregular bleeding
Prolonged bleeding
At one year:
No monthly bleeding
Infrequent bleeding

- Irregular bleeding

Headaches

Mood changes

Less sex drive

Dizziness


Weight gain (see Question 4, p. 78)

Abdominal bloating and discomfort

- Cause no monthly bleeding (for many women)
- May help women to gain weight



Progestin-Only Injectables 61





60



Progestin-Only Injectables

Known Health Benefits

DMPA

Helps protect against:

- Risks of pregnancy
- Cancer of the lining of the uterus (endometrial cancer)
- Uterine fibroids

May help protect against:

- Symptomatic pelvic inflammatory disease
- Iron-deficiency anemia

Reduces:

- Sickle cell crises among women with sickle cell anemia
- Symptoms of endometriosis (pelvic pain, irregular bleeding)

NET-EN

Helps protect against:

None

Iron-deficiency anemia

NET-EN may offer many of the same health benefits as DMPA, but this list of benefits includes only those for which there is available research evidence.

Correcting Misunderstandings (see also Questions and Answers, p. 78)

Progestin-only injectables:

- Can stop monthly bleeding, but this is not harmful. It is similar to not having monthly bleeding during pregnancy. Blood is not building up inside the woman.
- Do not disrupt an existing pregnancy.
- Do not make women infertile.

New Formulation of DMPA

A formulation of DMPA has been developed specifically for injection into the tissue just under the skin (subcutaneously). This new formulation *must* be delivered by subcutaneous injection. It will not be completely effective if injected in other ways. (Likewise, DMPA for injection into the muscle must not be injected subcutaneously.)


The hormonal dose of the new subcutaneous formulation (DMPA-SC) is 30% less than for DMPA formulated for injection into the muscle— 104 mg instead of 150 mg. Thus, it may cause fewer side effects, such as weight gain. Contraceptive effectiveness is similar. Like users of intramuscular DMPA, users of DMPA-SC have an injection every 3 months.

DMPA-SC will be available in prefilled syringes, including the single-use Uniject system. These prefilled syringes will have special short needles meant for subcutaneous injection. With these syringes, women could inject DMPA themselves. DMPA-SC was approved by the United States Food and Drug Administration in December 2004 under the name "depo-subQ provera 104." It has since also been approved in the United Kingdom.



62 Family Planning: A Global Handbook for Providers

Progestin-Only Injectables 63





Known Health Risks

None

New Problems That May Require Switching Methods

May or may not be due to the method.

Migraine headaches (see Identifying Migraine Headaches and Auras, p. 368)

- If she has migraine headaches without aura, she can continue to use the method if she wishes.
- If she has migraine aura, do not give the injection. Help her choose a method without hormones.

Unexplained vaginal bleeding (that suggests a medical condition not related to the method)

Progestin-Only Injectabl

- Refer or evaluate by history and pelvic examination. Diagnose and treat as appropriate.
- If no cause of bleeding can be found, consider stopping progestin-only injectables to make diagnosis easier. Provide another method of her choice to use until the condition is evaluated and treated (not implants or a copper-bearing or hormonal IUD).
- If bleeding is caused by sexually transmitted infection or pelvic inflammatory disease, she can continue using progestin-only injectables during treatment.

Certain serious health conditions (suspected blocked or narrowed arteries, liver disease, severe high blood pressure, blood clots in deep veins of legs or lungs, stroke, breast cancer, or damage to arteries, vision, kidneys, or nervous system caused by diabetes). See Signs and Symptoms of Serious Health Conditions, p. 320.

- Do not give next injection.
- Give her a backup method to use until the condition is evaluated.
- Refer for diagnosis and care if not already under care.

Suspected pregnancy

- Assess for pregnancy.
- Stop injections if pregnancy is confirmed.
- There are no known risks to a fetus conceived while a woman is using injectables (see Question 11, p. 80).

Questions and Answers About Progestin-Only Injectables

Can women who could get sexually transmitted infections (STIs) use progestin-only injectables?

Yes. Women at risk for STIs can use progestin-only injectables. The few studies available have found that women using DMPA were more likely to acquire chlamydia than women not using hormonal contraception. The reason for this difference is not known. There are few studies available on use of NET-EN and STIs. Like anyone else at risk for STIs, a user of progestin-only injectables who may be at risk for STIs should be advised to use condoms correctly every time she has sex. Consistent and correct condom use will reduce her risk of becoming infected if she is exposed to an STI.

If a woman does not have monthly bleeding while using progestin-only injectables, does this mean that she is pregnant?

Probably not, especially if she is breastfeeding. Eventually most women using progestin-only injectables will not have monthly bleeding. If she has been getting her injections on time, she is probably not pregnant and can keep using injectables. If she is still worried after being reassured, she can be offered a pregnancy test, if available, or referred for one. If not having monthly bleeding bothers her, switching to another method may help.

Can a woman who is breastfeeding safely use progestin-only injectables?

Yes. This is a good choice for a breastfeeding mother who wants a hormonal method. Progestin-only injectables are safe for both the mother and the baby starting as early as 6 weeks after childbirth. They do not affect milk production.

4. How much weight do women gain when they use progestin-only injectables?


Women gain an average of 1-2 kg per year when using DMPA. Some of the weight increase may be the usual weight gain as people age. Some women, particularly overweight adolescents, have gained much more than 1-2 kg per year. At the same time, some users of progestin-only injectables lose weight or have no significant change in weight. Asian women in particular do not tend to gain weight when using DMPA.

5. Do DMPA and NET-EN cause abortion?

No. Research on progestin-only injectables finds that they do not disrupt an existing pregnancy. They should not be used to try to cause an abortion. They will not do so.

78 Family Planning: A Global Handbook for Providers







For more information

Contact: reproductivehealth@who.int



